Developing next-generation macromolecule therapeutics

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement.
The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity.
This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Science

The Challenge: Endolysosomal trapping of macromolecules

One of the greatest challenges for efficacy of macromolecule therapeutics that act on an intracellular level, is delivery into key cells. Macromolecule therapeutics nowadays rely on receptor-mediated endocytosis into the endosomal compartment. The endo-lysosomal membranes, however, prohibit efficient cytoplasmic access of such foreign substances. The therapeutic efficacy of such drugs is therefore highly dependent on endo-lysosomal vesicles degradation.
Cytosolic delivery of macromolecule therapeutics requires incredibly challenging technical optimizations or specialized drug delivery platforms. For most oligonucleotide-based therapeutics, delivery remains an unsolved problem and exposes a significant need for the development of novel delivery mechanisms.

Our Approach: ENDOSCAPE®

At Sapreme, we are developing improved macromolecule delivery mechanisms by circumventing endosomal entrapment. Our ENDOSCAPE® platform is based on compounds which can release trapped cargo from the endo-lysosomal membranes, improving the therapeutic window and enabling access to intracellular targets with minimal toxicity.
By binding our technology to antibody-conjugated toxins and oligonucleotides, our goal is to enhance target engagement and improve therapeutic efficacy without limitation to biologic modality or indication.

News & Events

Press Releases:

October 7, 2021

Sapreme Boosts Development of its Endosomal Escape Technology Platform and Proprietary Pipeline with EUR 15M Series A

Sapreme, a biotechnology company focused on improving the delivery and efficacy of macromolecule therapeutics, today announced that it has closed a EUR 15 million Series A financing round to accelerate the buildout of its endosomal escape technology platform and support the further progress of its proprietary pipeline and corporate development activities. Led by founding investor Aglaia Oncology Funds, together with Aglaia-associated partners, the round follows promising 2020 and 2021 preclinical data demonstrating the effectiveness of Sapreme’s endosomal escape compound, SPT001. Read the full release here.

September 27, 2021

Sapreme presents Promising New Preclinical Data at 17th Annual Meeting of Oligonucleotide Therapeutics Society.

January 21, 2021

Sapreme Appoints Henrik Luessen as Chief Business Officer

December 17, 2020

Sapreme Appoints Björn Cochlovius as Chairman of its Board of Directors

October 27, 2020

Sapreme Appoints Miriam Bujny as Chief Development Officer

September 28, 2020

Sapreme Unveils its Proprietary Endosomal Escape Platform in Presentations at 16th Annual Meeting of Oligonucleotide Therapeutics Society

Events:

Upcoming events:
November 29-30, 2021

Sapreme’s Chief Development Officer Miriam Bujny will be speaking at the BioTech Pharma Summit 2021. The topic of her talk will be “Antibody-targeted cytoplasmic delivery of oligonucleotide- or protein conjugates using Sapreme’s endosomal escape enhancers”. She will be presenting data demonstrating how Sapreme’s SPT001 can deliver pharmaceutically relevant amounts of antibodies and antibody conjugates to the cytoplasm or nucleus in a tissue-specific manner, and provide perspective on ongoing developments.

Past events:

September 23rd, 2021

Guy Hermans (CEO) will be speaking at the online SMI Oligonucleotide Therapeutics and Delivery Conference. In his spotlight session titled  “Targeted Cytoplasmic Delivery of Oligonucleotides”, he will present how Sapreme’s SPT001 compound enables intracellular delivery of non-membrane permeable biomolecules by enhancing their escape from the endosome. Furthermore, he will highlight recent proof-of-principle studies on nucleic acid delivery in vitro and in vivo, and provide perspective on ongoing developments.

September 26-29, 2021

Sapreme will be presenting novel validation data on its endosomal escape technology at the upcoming 17th Annual Meeting of the Oligonucleotide Therapeutics Society. In his short presentation “Efficient on-target delivery of oligonucleotides to the liver and beyond: in vivo performance of Sapreme’s endosomal escape enhancers”, Guy Hermans will showcase data highlighting in vivo gene knock-down in the liver at substantially reduced oligonucleotide doses through the use of SPT001 conjugation technology. Furthermore, results will be shared showing persistence of PD effects, and how tuning of coupling chemistry and SPT001 loading allow for further dose reductions.

About Sapreme:

Sapreme’s mission is to develop next-generation macromolecule therapeutics by circumventing endosomal entrapment, thereby enhancing target engagement. The company’s proprietary endosomal escape platform improves the therapeutic window by enabling access to intracellular targets with minimal toxicity. This approach is applied for Sapreme’s internal pipeline and is available for partnering, without limitation to biologic modality or indication.

Contacts:
Guy Hermans, CEO
+31 30 760 09 76
hermans@sapreme-technologies.com

For Media Inquiries, please contact:
Trophic Communications
Eva Mulder or Valeria Fisher
+49 89 238 877 30
sapreme@trophic.eu

Careers

If you are a talented individual interested in contributing to our mission, please send your resume to 

info@sapreme-technologies.com

Contact

Telephone

+31 30 760 09 76

Address

LSI, Room 2.09
Yalelaan 62
3584 CM Utrecht
The Netherlands